Terns Pharmaceuticals, Inc. (TERN) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts TERN Hot Sheet
Join SI Premium – FREE
Terns Pharmaceuticals, Inc. (NASDAQ: TERN) reported Q2 EPS of ($0.31), $0.03 better than the analyst estimate of ($0.34).
For earnings history and earnings-related data on Terns Pharmaceuticals, Inc. (TERN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UnitedHealth Group (UNH) Tops Q3 EPS by 57c, Beats on Revenue; Offers FY EPS Guidance
- Bernstein SocGen on Apple (AAPL): 'December guide may disappoint'
- Bristol-Myers Squibb Co. (BMY) PT Lowered to $60 at Wells Fargo
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
